Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
"MERCK SHARP & DOHME (NEW ZEALAND) LIMITED, Consumer",Pembrolizumab,Biliary tract cancer,Pembrolizumab (Keytruda),Options for investment,,Oncology Agents and Immunosuppressants
